BioSpace News Archive

Approach: Clinical interest in intratumoral therapy is increasing because of advancements in interventional oncology and growing recognition of the importance of treating the primary tumor across the disease spectrum. Clinical trials are underway by NanOlogy in multiple therapeutic areas to evaluate local delivery of concentrated, sustained chemotherapies to increase solid tumor response, eliminate toxicities associated with systemic agents, and promote favorable immunomodulation.

Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer.

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single-cell RNA sequencing and genomic analysis to develop life-changing medicines.

Kadmon Holdings was acquired by Sanofi in 2021.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth.

Starton Therapeutics is a clinical-stage biotechnology company that is transforming standard-of-care therapies with proprietary dermal technology, so people with cancer can receive continuous treatment to live better, longer.

Tiburio Therapeutics is now a part of Mallinckrodt Pharmaceuticals.

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins. By changing the activity of proteins that modify messenger RNA, we aim to develop new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases.

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™) therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable.

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths.